Arbor Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH126768D
- Pages: 29
- October 2018
- Total Views:1272
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Arbor Pharmaceuticals LLC (Arbor) is a specialty pharmaceutical company that offers prescription and generic products. The company offers medicines in the therapeutic areas of cardiology, pediatrics, and neuroscience, generics, and hospital and specialty markets. Its lead products under phase 3 stage include AR06, AR19 and AR25; and under phase 1 stage includes AR20. The company's partnered products under phase1 stage include AR29 and AR30; and under phase 3 stage includes AR28. It also provides licensing, manufacturing, development and commercialization of late-stage prescription products. Arbor also develops both new chemical entities and already approved molecules for new indications or in improved dosage forms. The company offers products, which are used in treatment areas such as cardiovascular, emergency, pediatrics, psychiatry, oncology, dermatology, urology, and endocrinology diseases. The company markets its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US.
Arbor Pharmaceuticals LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
Venture Financing 13
XenoPort Raises USD20 Million in Venture Financing 13
Private Equity 14
KKR to Acquire Minority Stake in Arbor Pharma 14
Partnerships 15
Debiopharm Enters into Distribution Agreement with Arbor Pharma 15
Licensing Agreements 16
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18
Equity Offering 19
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19
XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20
XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21
Debt Offering 22
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22
Acquisition 24
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC-Key Competitors 26
Arbor Pharmaceuticals LLC-Key Employees 27
Arbor Pharmaceuticals LLC-Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List Of Figure
List of Figures
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List Of Table
List of Tables
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
XenoPort Raises USD20 Million in Venture Financing 13
KKR to Acquire Minority Stake in Arbor Pharma 14
Debiopharm Enters into Distribution Agreement with Arbor Pharma 15
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19
XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20
XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC, Key Competitors 26
Arbor Pharmaceuticals LLC, Key Employees 27
Arbor Pharmaceuticals LLC, Subsidiaries 28
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Arbor Pharmaceuticals LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Arbor Pharmaceuticals LLC (Arbor) is a specialty pharmaceutical company that offers prescription and generic products. The company offers medicines in the therapeutic areas of cardiology, pediatrics, and neuroscience, generics, and hospital and specialty markets. Its lead products under phase 3 stage include AR06, AR19 and AR25; and under phase 1 stage includes AR20. The company's partnered products under phase1 stage include AR29 and AR30; and under phase 3 stage includes AR28. It also provides licensing, manufacturing, development and commercialization of late-stage prescription products. Arbor also develops both new chemical entities and already approved molecules for new indications or in improved dosage forms. The company offers products, which are used in treatment areas such as cardiovascular, emergency, pediatrics, psychiatry, oncology, dermatology, urology, and endocrinology diseases. The company markets its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US.
Arbor Pharmaceuticals LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
Venture Financing 13
XenoPort Raises USD20 Million in Venture Financing 13
Private Equity 14
KKR to Acquire Minority Stake in Arbor Pharma 14
Partnerships 15
Debiopharm Enters into Distribution Agreement with Arbor Pharma 15
Licensing Agreements 16
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18
Equity Offering 19
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19
XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20
XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21
Debt Offering 22
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22
Acquisition 24
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC-Key Competitors 26
Arbor Pharmaceuticals LLC-Key Employees 27
Arbor Pharmaceuticals LLC-Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List Of Figure
List of Figures
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List Of Table
List of Tables
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
XenoPort Raises USD20 Million in Venture Financing 13
KKR to Acquire Minority Stake in Arbor Pharma 14
Debiopharm Enters into Distribution Agreement with Arbor Pharma 15
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19
XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20
XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24
Arbor Pharmaceuticals LLC, Key Competitors 26
Arbor Pharmaceuticals LLC, Key Employees 27
Arbor Pharmaceuticals LLC, Subsidiaries 28
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Arbor Pharmaceuticals LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.